Ozempic Dosing Schedule
Start Ozempic at 0.25 mg subcutaneously once weekly for 4 weeks, then increase to 0.5 mg weekly, and if additional glycemic control is needed after at least 4 weeks, escalate to the maximum dose of 1 mg once weekly. 1
Standard Titration Protocol
The FDA-approved dosing schedule follows a structured escalation pattern 1:
Weeks 1-4: 0.25 mg subcutaneously once weekly
- This is a treatment initiation dose only and is not effective for glycemic control
- Serves to minimize gastrointestinal side effects during initiation
Week 5 onward: 0.5 mg once weekly
- This is the first therapeutic maintenance dose
Optional escalation: 1 mg once weekly
- Increase only if additional glycemic control is needed after at least 4 weeks on 0.5 mg
- This is the maximum recommended dose for type 2 diabetes
Administration Guidelines
Timing and flexibility:
- Administer on the same day each week, at any time of day, with or without meals 1
- The day of weekly administration can be changed if the time between doses is at least 2 days (>48 hours) 1
Missed dose protocol:
- If a dose is missed, administer as soon as possible within 5 days 1
- If more than 5 days have passed, skip the missed dose and resume the regular schedule 1
Injection sites:
- Rotate between abdomen, thigh, or upper arm 1
- Use a different injection site each week when injecting in the same body region
Higher Dose Formulations for Obesity
For weight management (marketed as Wegovy), a different titration schedule applies with escalation to 2.4 mg weekly 2, 3, 4:
- 0.25 mg weekly × 4 weeks
- 0.5 mg weekly × 4 weeks
- 1.0 mg weekly × 4 weeks
- 1.7 mg weekly × 4 weeks
- 2.4 mg weekly (maintenance dose)
This extended titration over 16 weeks minimizes gastrointestinal adverse effects 3.
Renal Dosing Considerations
No dosage adjustments are required for renal impairment 2. This is a significant advantage over other GLP-1 receptor agonists like exenatide (not recommended with eGFR <45) or lixisenatide (not recommended with CrCl <15) 2.
Key Clinical Pitfalls
Gastrointestinal side effects: The slow titration schedule is critical—nausea, vomiting, and diarrhea are most prominent at initiation and usually improve over time 5, 6. Mitigation strategies include smaller meals, stopping eating when not hungry, and avoiding spicy foods 6.
Hypoglycemia risk: When combining with insulin or sulfonylureas, reduce doses of these agents proactively and counsel patients on hypoglycemia symptoms 5, 3. Semaglutide alone carries very low hypoglycemia risk due to glucose-dependent insulin secretion 3.
Diabetic retinopathy: Rapid glucose lowering in patients with marked hyperglycemia and preexisting retinopathy may transiently worsen retinopathy—ensure regular ophthalmologic monitoring in high-risk patients 5, 6.
Drug interactions: Do not combine with other GLP-1 receptor agonists or DPP-4 inhibitors (redundant mechanisms) 6, 3. May delay gastric emptying and affect absorption of oral medications requiring rapid onset 3.